Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update.</li><li>The company recently completed a public offering for gross proceeds of approximately $4.75 million.</li><li>This capital infusion is important as the company prepares to initiate a second Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of cutaneous T cell lymphoma (CTCL).</li></ul>

On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update.The company recently completed a public offering for gross proceeds of approximately $4.75 million.This capital infusion is important as the company prepares to initiate a second Phase 3 trial of HyBryte (synthetic hypericin) in the treatment of cutaneous T cell lymphoma (CTCL).

SNGX: Second Confirmatory Phase 3 Trial of HyBryte  in CTCL to Initiate Before End of 2024 

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

<ul>
<li>Cheerwin is a strong turnaround story with significant earnings growth in 2023 with solid dividend yield. It is the number one player in the inspect repellent sector in China. </li>
<li>Cheerwin's current price is 79% lower than the IPO  price. However, Cheerwin's shares are up 35% YTD, sharply outperforming Hang Seng index which is up 13.6% YTD.</li>
<li>We found Cheerwin (6601 HK) using Smartkarma's Smart Score Screener system. We used the following screening methodology: Market cap - More than $300 million Dividends = 5 only.</li>
</ul>


Cheerwin is a strong turnaround story with significant earnings growth in 2023 with solid dividend yield. It is the number one player in the inspect repellent sector in China. 
Cheerwin's current price is 79% lower than the IPO  price. However, Cheerwin's shares are up 35% YTD, sharply outperforming Hang Seng index which is up 13.6% YTD.
We found Cheerwin (6601 HK) using Smartkarma's Smart Score Screener system. We used the following screening methodology: Market cap - More than $300 million Dividends = 5 only.


Asian Dividend Gems: Cheerwin - Number One Provider of Mosquito Repellents in China

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

10 in 10 with OUE Healthcare - Sustainable Expansion across Asia

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/tencent-holdings-ltd" target="_blank" data-smartkarma-citation="entities:26:1" rel="noopener">Tencent (700 HK)</a> reported 1Q2024 results today. Both revenues and OP grew 6.3% and 30.0% YoY respectively and beat consensus estimates.</li>
<li>Though domestic games revenues declined YoY, there were signs of recovery in Tencent’s gaming business. Online advertising saw strong growth despite 1Q being a seasonally weak quarter for Tencent.</li>
<li>Tencent’s investments in high-margin products have helped boost the company’s margins across all business segments.</li>
</ul>



Tencent (700 HK) reported 1Q2024 results today. Both revenues and OP grew 6.3% and 30.0% YoY respectively and beat consensus estimates.
Though domestic games revenues declined YoY, there were signs of recovery in Tencent’s gaming business. Online advertising saw strong growth despite 1Q being a seasonally weak quarter for Tencent.
Tencent’s investments in high-margin products have helped boost the company’s margins across all business segments.


Tencent: Online Advertising and High-Margin Businesses Support Earnings

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company reported 1Q2024 results that were a little shy of estimates, but growth continues, and the product line should accelerate growth in the coming years.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company reported 1Q2024 results that were a little shy of estimates, but growth continues, and the product line should accelerate growth in the coming years.

SCLX:  Making Decisions That Should Boost Revenue

SNGX: Second Confirmatory Phase 3 Trial of HyBryte in CTCL to Initiate Before End of 2024

On May 10, 2024, Soligenix, Inc. (SNGX) announced financial results for the first quarter of 2024 and provided a business update. The company...

Zacks Small Cap Research

Asian Dividend Gems: Cheerwin - Number One Provider of Mosquito Repellents in China

Cheerwin is a strong turnaround story with significant earnings growth in 2023 with solid dividend yield. It is the number one player in the...

Douglas Kim

10 in 10 with OUE Healthcare - Sustainable Expansion across Asia

10 in 10 with OUE Healthcare - Sustainable Expansion across Asia

Singapore Exchange Ltd (SGX)

Tencent: Online Advertising and High-Margin Businesses Support Earnings

Tencent's 1Q earnings beat consensus. Though online games declined there were signs of recovery. Online ad saw strong growth despite 1Q being...

Shifara Samsudeen, ACMA, CGMA

SCLX: Making Decisions That Should Boost Revenue

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research